StreetAlpha.app
Home › Stocks › KRYS

Krystal Biotech, Inc. (KRYS)

Healthcare
$298.55
▲ +0.22%
LAST CLOSE · NOV 17

Krystal Biotech develops and makes gene therapies, including VYJUVEK, a topical treatment for a rare inherited skin disease. It last closed at $298.55 on Nov 17, up 0.22% on the day. The average 12-month price target from 6 analysts is $394.83 (+32.3% from the last close), with a high of $441.00 and a low of $361.00. Analyst consensus is Strong Buy, based on the latest ratings from 6 firms (6 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 2 whale options trades in KRYS, 50% of them bullish and 50% bearish.

AI Auto Pilots
Is KRYS in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$470.0M
+26.0% vs a year ago
Net income
$225.2M
+13.2% vs a year ago
EPS (diluted)
$7.36
+10.3% vs a year ago
Free cash flow
$310.1M
66.0% margin
Valuation
Market cap
$8.8B
29.6M shares
P/E
40.6
Price over 12 month EPS
Price to sales
18.8
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$462.8M
At Sep 30
Shareholder equity
$1.4B
Shares outstanding
29.6M
At Oct 28
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $0$0FY2021FY2022: $0$0FY2022FY2023: $50.7M$50.7MFY2023FY2024: $290.5M$290.5MFY2024FY2025: $389.1M$389.1MFY2025

From KRYS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 2). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 6 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
6firms
6 Buy0 Hold0 Sell
Each firm's latest rating on KRYS in the past 90 days
Average 12-month target
$394.83
▲ 32.3% upside

Based on 6 analysts who set a price target on KRYS in the past 90 days. The average target is $394.83, with a high of $441.00 and a low of $361.00, compared with the last close of $298.55.

Low $361.00Avg $394.83High $441.00
Blue marker: last close $298.55
Highest target$441.00
Average target$394.83
Lowest target$361.00
Latest rating changes
CitigroupTarget raised
Nov 3Buy$386 → $412
TD CowenTarget lowered
Nov 3Buy$403 → $380
RBC CapitalTarget lowered
Nov 3Buy$400 → $375
HC Wainwright & Co.Target raised
Oct 15Buy$221 → $361
HC Wainwright & Co.Maintained
Sep 25Buy$221
DateFirmActionRatingPrice target
Nov 3CitigroupTarget raisedBuy$386 → $412
Nov 3TD CowenTarget loweredBuy$403 → $380
Nov 3RBC CapitalTarget loweredBuy$400 → $375
Oct 15HC Wainwright & Co.Target raisedBuy$221 → $361
Sep 25HC Wainwright & Co.MaintainedBuy$221
Loading…

Technical Analysis

KRYS · as of the Nov 17 close · updated after every close
Turning down

The stock is 4% below its 20 day and 9% below its 50 day average. It is 4% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 40). The nearest support is the Pivot at $297.85, and the nearest resistance the Pivot R1 at $300.64.

Short trendBearish
Long trendNeutral
MomentumWeak
StretchNormal
VolatilityNormal, 3.5%/day
Key levels
$382.5452 week high+28.1%
$336.92100 day average+12.9%
$324.5050 day average+8.7%
$310.93Swing high (Nov 11)+4.1%
$310.2520 day average+3.9%
$309.88200 day average+3.8%
$300.64Pivot R1+0.7%
$298.55Last close
$297.85Pivot−0.2%
$297.52Swing low (Nov 9)−0.3%
$295.76Pivot S1−0.9%
$202.9952 week low−32.0%
Indicators
RSI (14)39.62Weak, oversold below 30Neutral
MACD-7.03Below its signal lineBearish
Stochastic37.4Middle of its rangeNeutral
ADX (14)19.1No clear trend
Williams %R-66.5Oversold below −80, overbought above −20Neutral
CCI (20)-99.3Oversold below −100, overbought above 100Neutral
Rate of change−2.1%Change over 10 sessionsBearish
ATR (14)$10.58Typical daily range, 3.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for KRYS

What happened before

See how KRYS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow KRYS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How KRYS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
2
Bullish
1
50%
Bearish
1
50%
Date span
Aug 21 – Oct 19
Loading…

See today’s whale options flow across the market →

KRYS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲256 buying vs 177 selling
  • ▼Held by funds -4.4 pts
  • ▲Funds holding +16
  • ▲Superinvestors: 3 added, 0 cut
  • ▼Put/call 2.02 to 3.30
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding442426+3.8%
In funds' top 10912−25.0%
Held by funds97.9%102.2%−4.4 pts
New / increased76 / 18091 / 175−3.8%
Reduced / sold out122 / 55110 / 37+20.4%
Put/call ratio3.302.02+63.8%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See KRYS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether KRYS is in one of them and how their past KRYS trades turned out.

KRYS in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered KRYS in an article yet. Here's the latest on the wider market.

KRYS Congress Trades

All congress trades →
Trades, 12 months
2
Buys
0
0%
Sells
2
100%
People
1
Last filed Sep 22
Who traded KRYS · since 2022
Latest 3 filings
$100K – $250KTraded Jul 24, 2026Filed Sep 22, 2026
$15K – $50KTraded May 15, 2026Filed Jul 1, 2026
$1K – $15KTraded Dec 12, 2022Filed Jan 20, 2023
PersonTypeAmountTradedFiledDelay
Donald J TrumpExecutive branchSell$100K – $250KJul 24, 2026Sep 22, 202660 d
Donald J TrumpExecutive branchSell$15K – $50KMay 15, 2026Jul 1, 202647 d
Christopher JacobsR · NYBuy$1K – $15KDec 12, 2022Jan 20, 202339 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Krystal Biotech

Krystal Biotech is a biotechnology company based in Pittsburgh, Pennsylvania, that develops and manufactures gene therapies. Its platform uses an engineered herpes simplex virus to deliver therapeutic genes to target cells. Its approved product, VYJUVEK, is applied directly to the skin to treat dystrophic epidermolysis bullosa, a rare inherited skin disease, and is sold in the United States, Europe and Japan. The company also has clinical stage candidates for other rare diseases.

Headquarters
Pittsburgh, PA